



Generation Program

ALZHEIMER'S PREVENTION INITIATIVE

Alzheimer's Prevention Initiative Generation Program data now accessible to researchers

Researchers can now use the AD Workbench from the Alzheimer's Disease Data Initiative to request access to data from the Alzheimer's Prevention Initiative (API) Generation Studies 1 and 2, two of the world's first Alzheimer's prevention trials of investigational amyloid-modifying drug therapies in persons with the major genetic risk factor for the disease.

Data can be used to characterize cognitive and biomarker alterations in an exceptionally large number of cognitively unimpaired older adults with one or two copies of the APOE4 gene, and the initial impact of an investigational active amyloid beta immunotherapy and BACE inhibitor in the prevention of Alzheimer's Disease.

The API Generation Program:

- API Generation Study 1 (NCT0256551) was designed to evaluate cognitive, clinical and biomarker effects of the investigational beta-secretase (BACE1) inhibitor umibecestat and the investigational amyloid beta immunotherapy (i.e., vaccine) CAD106 in cognitively unimpaired 60-75 year-old APOE4 homozygotes (i.e., those with two copies of this gene), including those with or without elevated brain amyloid. Results found at <https://pubmed.ncbi.nlm.nih.gov/38145469/>
- API Generation Study 2 (NCT03131453) was designed to evaluate umibecestat's effects in a cognitively unimpaired 60-75 year-old APOE4 carriers (APOE4 homozygotes and heterozygotes); APOE4 heterozygotes (i.e., those with one copy of the gene) were required to have elevated brain amyloid.

Chance to assess early biological, cognitive changes:

While the studies were discontinued early due to mild (but ultimately reversible) cognitive worsening in persons treated with umibecestat, the data and related biological samples will give researchers a chance to further assess some of the earliest biological and cognitive changes associated with the predisposition to the disease, evaluate initial effects of the two investigational anti-amyloid treatments, and help inform the design of future prevention trials. The Generation Program study design can be found at <https://pubmed.ncbi.nlm.nih.gov/31211217/>.

The Generation Program was funded by Novartis Pharma AG, Basel, Switzerland, and Amgen, Thousand Oaks, CA, USA, in collaboration with the Banner Alzheimer's Institute, Phoenix, AZ, USA. Generation Study 1 was supported by funding from the National Institute on Aging, part of the NIH (1U1AG046150), as well as the Alzheimer's Association, FBRI, the GHR Foundation and the Banner Alzheimer's Foundation.

Visit alzheimerspreventioninitiative.com to learn more

How to Access Data:

- To access data, visit <https://www.alzheimersdata.org/ad-workbench> and search "Generation" or "Banner" to find our clinical trial data.
- Or contact APIData@bannerhealth.com
- The AD Workbench is a global, cloud-based platform with cutting-edge tools and resources that allow researchers to study, analyze, and compare data in new ways and uncover previously unseen insights. It's available to users at no cost.
- Data comes from the Alzheimer's Prevention Initiative, an international research collaboration led by Banner Alzheimer's Institute that includes public and private partners.
- The AD Workbench is interoperable with other data sharing platforms such as DPUK, EPND, GAAIN, and Vivli, and can serve as a connective thread through research projects and data sources.

Scan the QR code to learn more

